- BySeeking Alpha-
Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Technology, Consumer Services and Oil & Gas sectors led shares higher. At the close in NYSE,...
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced that it has completed patient enrollment in the phase III ILLUMINATE-301 study, evaluating tilsotolimod in combination with...
Axovant Gene Therapies Ltd. (NASDAQ:AXGT) announced that the FDA has granted an Orphan Drug designation to its investigational gene therapy candidate, AXO-AAV-GM1, being...
As of late, it has definitely been a great time to be an investor in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) . The stock has moved higher by 25% in the past month, while it is...
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.